RT Journal Article
T1 Clinical presentation and time-course of postoperative venous thromboembolism: Results from the RIETE Registry
A1 Arcelus, Juan Ignacio
A1 Monreal, Manuel
A1 Caprini, Joseph A
A1 Gutiérrez Guisado, Javier
A1 Soto, Mª José
A1 Núñez, Manuel Jesús
A1 Alvárez, Juan Carlos
K1 Ancianos
K1 Argentina
K1 Europa ( Continente)
K1 Femenino
K1 Fibrinolíticos
K1 Hemorragia
K1 Humanos
K1 Incidencia
K1 Israel
K1 Masculino
K1 Mediana edad
K1 Neoplasias
K1 Procedimientos ortopédicos
K1 Estudios prospectivos
K1 Embolia pulmonar
K1 Recurrencia local de neoplasia
K1 Sistema de registros
K1 Procedimientos quirúrgicos
K1 Factores de tiempo
K1 Tromboembolia venosa
K1 Surgery
K1 Venous thromboembolism
AB There is little literature about the clinical presentation and time-course of postoperative venous thromboembolism (VTE) in different surgical procedures. RIETE is an ongoing, prospective registry of consecutive patients with objectively confirmed, symptomatic acute VTE. In this analysis, we analysed the baseline characteristics, thromboprophylaxis and therapeutic patterns, time-course, and three-month outcome of all patients with postoperative VTE. As of January 2006, there were 1,602 patients with postoperative VTE in RIETE: 393 (25%) after major orthopaedic surgery (145 elective hip arthroplasty, 126 knee arthroplasty, 122 hip fracture); 207 (13%) after cancer surgery; 1,002 (63%) after other procedures. The percentage of patients presenting with clinically overt pulmonary embolism (PE) (48%, 48%, and 50% respectively), the average time elapsed from surgery to VTE (22 +/- 16, 24 +/- 16, and 21 +/- 15 days, respectively), and the three-month incidence of fatal PE (1.3%, 1.4%, and 0.8%, respectively), fatal bleeding (0.8%, 1.0%, and 0.2%, respectively), or major bleeding (2.3%, 2.9%, and 2.8%, respectively) were similar in the three groups. However, the percentage of patients who had received thromboprophylaxis (96%, 76% and 52%, respectively), the duration of prophylaxis (17 +/- 9.6, 13 +/- 8.9, and 12 +/- 11 days, respectively) and the mean daily doses of low-molecular-weight heparin (4,252 +/- 1,016, 3,260 +/- 1,141, and 3,769 +/- 1,650 IU, respectively), were significantly lower in those undergoing cancer surgery or other procedures. In conclusion, the clinical presentation, time-course, and three-month outcome of VTE was similar among the different subgroups of patients, but the use of prophylaxis in patients undergoing cancer surgery or other procedures was suboptimal.
PB Schattauer
SN 0340-6245
YR 2008
FD 2008-03-03
LK http://hdl.handle.net/10668/609
UL http://hdl.handle.net/10668/609
LA en
NO Arcelus JI, Monreal M, Caprini JA, Gutiérrez Guisado J, Soto MJ, Núñez MJ et al. Clinical presentation and time-course of postoperative venous thromboembolism: Results from the RIETE Registry.Thromb Haemost. 2008 Mar;99(3):546-51
NO Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't;
DS RISalud
RD Apr 18, 2025